Corinne Nantz
Gerontology · Fuquay Varina, NCNPI 1669951711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,066 and has fallen 98.8% since, to $25 in 2025. Among gerontology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 304 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$453
- AstraZeneca$450
- Amgen$405
- Boehringer Ingelheim$301
- AbbVie$285
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,806100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $1,028 |
| Lilly USA, LLC | 34 | $453 |
| AstraZeneca | 26 | $450 |
| Amgen | 32 | $405 |
| Boehringer Ingelheim | 17 | $301 |
| AbbVie | 20 | $285 |
| GSK | 13 | $211 |
| Sanofi-aventis U.S. LLC | 12 | $208 |
| Amarin Pharma, Inc. | 13 | $196 |
| Novartis | 8 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $123 |
| Pfizer | 7 | $115 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Exact Sciences | 4 | $85 |
| Bayer | 3 | $73 |
| Merck | 4 | $62 |
| Mylan Specialty L.p. | 4 | $60 |
| Medtronic | 2 | $58 |
| Johnson & Johnson | 4 | $57 |
| Abbott | 2 | $57 |
| Astellas Pharma US Inc | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Harmony Biosciences LLC | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $9 |
How this compares
$4,818 in reported general payments places this provider in the 95th percentile of 165 gerontology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 93 | $125,098 |
| JardianceEmpagliflozin | 95 | $99,248 |
| EliquisApixaban | 64 | $66,476 |
| TrulicityDulaglutide | 42 | $50,471 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $37,501 |
| MounjaroTirzepatide | 32 | $35,062 |
| FarxigaDapagliflozin Propanediol | 16 | $17,143 |
| VascepaIcosapent Ethyl | 27 | $14,502 |
| Repatha SyringeEvolocumab | 22 | $14,283 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,010 |
| Repatha SureclickEvolocumab | 23 | $12,291 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 49 | $10,836 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $9,783 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,861 |
| TrulancePlecanatide | 13 | $7,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,028 | $125,09893 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $301 | $112,257115 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $453 | $85,53374 claims |
| PfizerEliquis | $115 | $66,47664 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $211 | $57,199120 claims |
| AstraZenecaFarxiga | $450 | $17,14316 claims |
| MerckJanumet Xr | $62 | $9,78320 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $123 | $7,35213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 gerontology providers in North Carolina.
Other gerontology in Fuquay Varina
- Yvonne SpencerFuquay Varina$502
- Sharon BibyGreensboro$22K
- Lora StephensStatesville$12K
- Kimberly SmithRaleigh$10K
- Michelle WoodCharlotte$9K
- Taskeen MidgetteNew Bern$5K
- Brielle ReyesCary$4K
- Karen PattersonSouthern Pines$4K
- Morgan MillerRocky Mount$4K
- Chelsea CarlanReidsville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.